Frontiers in Immunology,
Journal Year:
2021,
Volume and Issue:
12
Published: Dec. 14, 2021
Emerging
evidence
supports
that
the
efficacy
of
immune
checkpoint
blockade
(ICB)
therapy
is
associated
with
host’s
gut
microbiota,
as
prior
antibiotic
intake
often
leads
to
poor
outcome
and
low
responsiveness
toward
ICB
treatment.
Therefore,
we
hypothesized
like
anti-programmed
cell
death
protein-1
(PD-1)
treatment
required
an
intact
host
it
was
established
probiotics
could
enhance
recovery
microbiota
disruption
by
external
stimuli.
Thus,
present
study
aimed
evaluate
effect
probiotics,
Lactobacillus
rhamnosus
Probio-M9,
on
recovering
antibiotic-disrupted
its
impact
in
tumor-bearing
mice.
We
first
disrupted
mouse
antibiotics
then
remediated
or
naturally.
Tumor
transplantation
performed,
followed
anti-PD-1-based
antitumor
therapy.
Changes
fecal
metagenomes
tumor
suppression
were
monitored
during
different
stages
experiment.
Our
results
showed
Probio-M9
synergized
therapy,
significantly
improving
inhibition
compared
groups
not
receiving
probiotic
(
P
<
0.05
at
most
time
points).
The
synergistic
accompanied
effective
restoration
microbiome
characterized
a
drastically
reduced
Shannon
diversity
value
shifted
composition
dominating
taxa.
Moreover,
administration
increased
relative
abundance
beneficial
bacteria
(e.g.,
Bifidobacterium
pseudolongum
,
Parabacteroides
distasonis
some
Bacteroides
species;
0.0001
0.05).
changes
mild
reshaping
functional
enrichment
sugar
degradation
vitamin
amino
acid
synthesis
pathways.
Collectively,
this
supported
immunotherapy,
be
potential
candidate
microbe-based
therapeutics.
preclinical
data
obtained
here
would
support
design
future
human
clinical
trials
for
further
consolidating
current
findings
safety
assessment
adjunctive
Nature Communications,
Journal Year:
2022,
Volume and Issue:
13(1)
Published: June 14, 2022
Abstract
Reactive
oxygen
species
(ROS)
play
vital
roles
in
intestinal
inflammation.
Therefore,
eliminating
ROS
the
inflammatory
site
by
antioxidant
enzymes
such
as
catalase
and
superoxide
dismutase
may
effectively
curb
bowel
disease
(IBD).
Here,
Escherichia
coli
Nissle
1917
(ECN),
a
kind
of
oral
probiotic,
was
genetically
engineered
to
overexpress
(ECN-pE)
for
treatment
To
improve
bioavailability
ECN-pE
gastrointestinal
tract,
chitosan
sodium
alginate,
effective
biofilms,
were
used
coat
via
layer-by-layer
electrostatic
self-assembly
strategy.
In
mouse
IBD
model
induced
different
chemical
drugs,
chitosan/sodium
alginate
coating
(ECN-pE(C/A)
2
)
relieved
inflammation
repaired
epithelial
barriers
colon.
Unexpectedly,
EcN-pE(C/A)
could
also
regulate
microbial
communities
abundance
Lachnospiraceae
_NK4A136
Odoribacter
flora,
which
are
important
microbes
maintain
homeostasis.
Thus,
this
study
lays
foundation
development
living
therapeutic
proteins
using
probiotics
treat
intestinal-related
diseases.
Chemical Reviews,
Journal Year:
2022,
Volume and Issue:
123(1), P. 31 - 72
Published: Nov. 1, 2022
The
human
microbiome
is
composed
of
a
collection
dynamic
microbial
communities
that
inhabit
various
anatomical
locations
in
the
body.
Accordingly,
coevolution
with
host
has
resulted
these
playing
profound
role
promoting
health.
Consequently,
perturbations
can
cause
or
exacerbate
several
diseases.
In
this
Review,
we
present
our
current
understanding
relationship
between
health
and
disease
development,
focusing
on
microbiomes
found
across
digestive,
respiratory,
urinary,
reproductive
systems
as
well
skin.
We
further
discuss
strategies
by
which
composition
function
be
modulated
to
exert
therapeutic
effect
host.
Finally,
examine
technologies
such
multiomics
approaches
cellular
reprogramming
microbes
enable
significant
advancements
research
engineering.
Exploration,
Journal Year:
2022,
Volume and Issue:
2(6)
Published: May 23, 2022
Immunotherapy
is
used
to
regulate
systemic
hyperactivation
or
hypoactivation
treat
various
diseases.
Biomaterial-based
immunotherapy
systems
can
improve
therapeutic
effects
through
targeted
drug
delivery,
immunoengineering,
etc.
However,
the
immunomodulatory
of
biomaterials
themselves
cannot
be
neglected.
In
this
review,
we
outline
with
functions
discovered
in
recent
years
and
their
applications
disease
treatment.
These
inflammation,
tumors,
autoimmune
diseases
by
regulating
immune
cell
function,
exerting
enzyme-like
activity,
neutralizing
cytokines,
The
prospects
challenges
biomaterial-based
modulation
are
also
discussed.
Exploration,
Journal Year:
2022,
Volume and Issue:
2(3)
Published: March 15, 2022
Immunotherapy
strategies
that
use
cell-based
delivery
systems
have
sparked
much
interest
in
the
treatment
of
malignancies,
owing
to
their
high
biocompatibility,
excellent
tumor
targeting
capability,
and
unique
biofunctionalities
growth
process.
A
variety
design
principles
for
immunotherapy,
including
cell
surface
decoration,
membrane
coating,
encapsulation,
genetically
engineered
cell,
cell-derived
exosomes,
give
cancer
immunotherapy
great
potential
improve
therapeutic
efficacy
reduce
adverse
effects.
However,
methods
is
still
limited,
practical
uses
are
hampered
due
complex
physiological
immunological
obstacles,
such
as
physical
barriers
immune
infiltration,
immunosuppressive
microenvironment,
upregulation
pathways,
metabolic
restriction.
In
this
review,
we
present
an
overview
maximize
impact,
along
with
anatomical,
metabolic,
impediments
using
treat
cancer.
Following
that,
a
summary
novel
been
created
overcome
these
obstacles
immunotherapeutic
provided.
Also,
prospects
next-step
development
concluded
end.
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: April 18, 2024
Abstract
Cancer,
a
complex
and
multifactorial
disease,
presents
significant
challenge
to
global
health.
Despite
advances
in
surgical,
radiotherapeutic
immunological
approaches,
which
have
improved
cancer
treatment
outcomes,
drug
therapy
continues
serve
as
key
therapeutic
strategy.
However,
the
clinical
efficacy
of
is
often
constrained
by
resistance
severe
toxic
side
effects,
thus
there
remains
critical
need
develop
novel
therapeutics.
One
promising
strategy
that
has
received
widespread
attention
recent
years
repurposing:
identification
new
applications
for
existing,
clinically
approved
drugs.
Drug
repurposing
possesses
several
inherent
advantages
context
since
repurposed
drugs
are
typically
cost-effective,
proven
be
safe,
can
significantly
expedite
development
process
due
their
already
established
safety
profiles.
In
light
this,
present
review
offers
comprehensive
overview
various
methods
employed
repurposing,
specifically
focusing
on
treat
cancer.
We
describe
antitumor
properties
candidate
drugs,
discuss
detail
how
they
target
both
hallmarks
tumor
cells
surrounding
microenvironment.
addition,
we
examine
innovative
integrating
with
nanotechnology
enhance
topical
delivery.
also
emphasize
role
play
when
used
part
combination
regimen.
To
conclude,
outline
challenges
associated
consider
future
prospects
these
transitioning
into
application.
Microorganisms,
Journal Year:
2022,
Volume and Issue:
10(10), P. 2048 - 2048
Published: Oct. 17, 2022
The
gut
microbiota
has
emerged
as
a
key
modulator
of
cancer
treatment
responses
in
terms
both
efficacy
and
toxicity.
This
effect
is
clearly
mediated
by
processes
impacting
the
activation
modulation
immune
responses.
More
recently,
ability
to
regulate
chemotherapeutic
drug
metabolism
also
driver
response,
although
direct
mechanisms
have
yet
be
fully
elucidated.
Through
fermentation,
can
produce
several
types
metabolites,
including
short-chain
fatty
acids
(SCFAs).
SCFAs
play
an
important
role
maintaining
epithelial
barrier
functions
intestinal
homeostasis,
with
recent
work
suggesting
that
modulate
response
treatments
influence
anti-tumor
inflammatory-related
side
effects.
In
this
review,
we
will
discuss
importance
their
implications
for
toxicities.
